Schrödinger, Inc. is a leading scientific software and biotechnology company specializing in the development of advanced computational tools for drug discovery and materials science. Founded in 1990 and headquartered in New York City, the company aims to transform molecular discovery through its physics-based computational platform, enabling the rapid and accurate design of novel molecules for therapeutic and material applications.
Key Strategic Focus
Schrödinger operates through two primary segments:
- Software Segment: This division licenses the company's computational platform to the life sciences and materials science industries, facilitating molecular discovery and design.
- Drug Discovery Segment: This segment focuses on building a portfolio of preclinical and clinical programs, both internally and through collaborations, leveraging the company's computational platform to advance drug discovery initiatives.
Financials and Funding
In the fiscal year ending December 31, 2024, Schrödinger reported total revenue of $242.4 million, reflecting a 19.7% year-over-year increase. The company achieved a net income of $40.7 million, a significant turnaround from a net loss of $149.2 million in the previous year. As of May 9, 2025, Schrödinger's stock (NASDAQ: SDGR) was trading at $23.91, with a market capitalization of approximately $1.75 billion.
Pipeline Development
Schrödinger's proprietary pipeline includes several key candidates:
- SGR-2921 (CDC7 Inhibitor): Granted Orphan Drug Designation by the FDA for the treatment of acute myeloid leukemia (AML). Initial clinical data from the ongoing Phase 1 study in patients with AML and myelodysplastic syndrome (MDS) is expected in the second half of 2025.
- SGR-1505 (MALT1 Inhibitor): Currently in a Phase 1 clinical study for patients with relapsed/refractory B-cell malignancies, with initial clinical data anticipated in the second quarter of 2025.
- SGR-3515 (Wee1/Myt1 Inhibitor): Undergoing a Phase 1 study in patients with advanced solid tumors, with initial clinical data expected in the second half of 2025.
Technological Platform and Innovation
Schrödinger's computational platform integrates physics-based methods with machine learning to predict molecular properties accurately. Key components include:
- Maestro: A comprehensive molecular modeling environment that serves as the interface for Schrödinger's suite of computational tools.
- Jaguar: An ab initio quantum chemistry package used for accurate electronic structure calculations.
- MacroModel: A molecular modeling program for conformational analysis and molecular dynamics simulations.
- PyMOL: A widely used molecular visualization system for rendering 3D structures of biomolecules.
Leadership Team
Schrödinger's leadership comprises experienced professionals dedicated to advancing computational drug discovery:
- Ramy Farid, Ph.D.: President and Chief Executive Officer.
- Michael Lynton: Chairman of the Board.
- P. L.: Chief Technology Officer and Chief Operating Officer, Software.
- M. D.: Chief Medical Officer.
- G. P.: Chief Financial Officer.
Competitor Profile
Schrödinger operates in a competitive landscape that includes:
- Certara: Provides biosimulation software and services to accelerate drug development.
- Instem: Offers IT solutions for the life sciences sector, focusing on data management and analysis.
- Dassault Systèmes Biovia: Delivers scientific software for molecular modeling and simulation.
The market for computational drug discovery is expanding, driven by the increasing complexity of drug targets and the need for efficient development processes. Schrödinger's integration of physics-based simulations with machine learning positions it favorably within this growing industry.
Strategic Collaborations and Partnerships
Schrödinger has established significant collaborations to enhance its research and development capabilities:
- Novartis: Entered a research collaboration and license agreement to develop small molecule candidates, with Schrödinger receiving an upfront payment of $150 million in January 2025.
- Eli Lilly: Expanded a research collaboration to include an additional undisclosed target under terms consistent with the existing agreement.
- Otsuka Pharmaceutical Co., Ltd.: Extended a research collaboration agreement to add another undisclosed target.
Operational Insights
Schrödinger's strategic focus on integrating physics-based simulations with machine learning differentiates it from competitors. The company's dual approach of software licensing and internal drug discovery programs allows for diversified revenue streams and mitigates risks associated with drug development.
Strategic Opportunities and Future Directions
Looking ahead, Schrödinger aims to:
- Enhance Software Capabilities: Continue investing in research and development to improve the accuracy and efficiency of its computational platform.
- Expand Collaborative Partnerships: Seek additional collaborations with pharmaceutical and biotechnology companies to co-develop drug candidates.
- Advance Proprietary Drug Programs: Progress internal drug discovery programs through clinical development stages to bring novel therapeutics to market.
- Explore Emerging Markets: Expand presence in regions investing in healthcare and biotechnology to tap into new customer bases.
Contact Information
- Website: www.schrodinger.com
- LinkedIn: Schrödinger LinkedIn Profile
- Instagram: Schrödinger Instagram Profile
Schrödinger's headquarters are located in New York, with additional offices in Cambridge, Framingham, Portland, San Diego, and international locations including Germany, the UK, India, Japan, Korea, and China.
